论文部分内容阅读
目的针对慢性胃炎采用雷贝拉唑与替普瑞酮联合治疗的患者康复影响分析。方法回顾性选取2016年5月—2017年4月收治的92例慢性胃炎患者,经胃内镜检查确诊,依据用药方案分两组,各46例。对照组给予雷贝拉唑,实验组施行两联用药加入替普瑞酮,分析两组患者治疗期间胃黏膜组织变化和症状康复相关情况。结果实验组治疗后EGFR细胞阳性(26.53±5.26)%高于对照组,慢性炎症评分(1.01±0.12)分和活动性炎症评分(1.03±0.21)分低于对照组(P<0.05);实验组上腹疼痛消失(5.92±1.47)d、腹胀消失(5.91±1.28)d和反酸消失(5.47±1.62)d相比对照组症状康复时间缩短(P<0.05)。结论慢性胃炎采用雷贝拉唑与替普瑞酮联合治疗有较好的临床疗效,患者不良体征康复时间缩短,各炎症反应评分降低,具有临床普及运用的价值。
Objective To investigate the rehabilitation effects of rabeprazole and teprenone in patients with chronic gastritis. Methods A total of 92 patients with chronic gastritis admitted from May 2016 to April 2017 were retrospectively selected and diagnosed by gastroscopy. The patients were divided into two groups (n = 46) according to the drug regimen. The rabbits in the control group were given rabeprazole. The experimental group was treated with teprenone in combination with two drugs, and the changes of gastric mucosal tissue and the recovery of symptoms during the two groups were analyzed. Results The positive rate of EGFR cells in the experimental group was significantly higher than that in the control group (26.53 ± 5.26% vs 1.01 ± 0.12 vs 1.03 ± 0.21, P <0.05) Compared with the control group, the recovery time was shorter (5.92 ± 1.47) d, disappearance of abdominal distension (5.91 ± 1.28) d and acid reflux disappearance (5.47 ± 1.62) d (P <0.05). Conclusion The combination therapy of rabeprazole and teprenone in chronic gastritis has better clinical curative effect, the recovery time of patients with bad signs is shortened, and the score of each inflammatory reaction is reduced, which has the value of clinical popularization and application.